TY - JOUR
T1 - Intravenous immunoglobulin versus placebo in recurrent pregnancy loss
T2 - A systematic review and meta-analysis of randomized trials
AU - Kofod, Louise
AU - Pedersen, Madicken
AU - Andersen, Mette
AU - Christensen, Emilie
AU - Pedersen, Pernille
AU - Alipour, Hiva
AU - Egerup, Pia
AU - Christiansen, Ole Bjarne
AU - Kesmodel, Ulrik Schiøler
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/8
Y1 - 2025/8
N2 - Recurrent pregnancy loss (RPL) affects 1–2 % of fertile couples, with immunological factors increasingly implicated in unexplained cases. Currently, no convincing treatment exists. Intravenous immunoglobulin (IVIg) has been explored as a potential treatment, but results have been inconsistent. This study evaluates whether IVIg affects live birth rates in women with RPL in subsequent pregnancies. We searched PubMed, Embase, and Cochrane libraries for relevant randomized controlled trials up to March 20, 2023, and contacted authors for individual patient data. Trials involving women with two or more consecutive pregnancy losses who received IVIg or placebo before or during the first trimester were included. Primary outcomes were live birth and clinical pregnancy rates, with secondary outcomes including pregnancy loss rate, side effects, adverse events, and perinatal outcomes. Risk of bias and certainty of evidence (GRADE) were evaluated. Ten studies involving 662 women were included. The intention-to-treat analysis showed no significant difference in live birth rates between IVIg and placebo groups (RR: 1.02, 95 % CI: 0.86–1.22, p = 0.78, GRADE: moderate). However, per-protocol analysis indicated an increased live birth rate with IVIg (RR: 1.23, 95 % CI: 1.00–1.50, GRADE: low). Live birth rates after IVIg improved with the number of previous losses, especially in patients with ≥ 6 losses (RR: 5.26 (1.58–17.53)). While IVIg therapy did not show a significant improvement in live birth rates overall, future research should focus on identifying specific patient subgroups, such as those with multiple prior losses, who may benefit most from this treatment.
AB - Recurrent pregnancy loss (RPL) affects 1–2 % of fertile couples, with immunological factors increasingly implicated in unexplained cases. Currently, no convincing treatment exists. Intravenous immunoglobulin (IVIg) has been explored as a potential treatment, but results have been inconsistent. This study evaluates whether IVIg affects live birth rates in women with RPL in subsequent pregnancies. We searched PubMed, Embase, and Cochrane libraries for relevant randomized controlled trials up to March 20, 2023, and contacted authors for individual patient data. Trials involving women with two or more consecutive pregnancy losses who received IVIg or placebo before or during the first trimester were included. Primary outcomes were live birth and clinical pregnancy rates, with secondary outcomes including pregnancy loss rate, side effects, adverse events, and perinatal outcomes. Risk of bias and certainty of evidence (GRADE) were evaluated. Ten studies involving 662 women were included. The intention-to-treat analysis showed no significant difference in live birth rates between IVIg and placebo groups (RR: 1.02, 95 % CI: 0.86–1.22, p = 0.78, GRADE: moderate). However, per-protocol analysis indicated an increased live birth rate with IVIg (RR: 1.23, 95 % CI: 1.00–1.50, GRADE: low). Live birth rates after IVIg improved with the number of previous losses, especially in patients with ≥ 6 losses (RR: 5.26 (1.58–17.53)). While IVIg therapy did not show a significant improvement in live birth rates overall, future research should focus on identifying specific patient subgroups, such as those with multiple prior losses, who may benefit most from this treatment.
KW - Habitual abortion
KW - Immunoglobulins
KW - Live birth
KW - Meta-analysis
KW - Systematic review
KW - Pregnancy
KW - Abortion, Habitual/immunology
KW - Immunoglobulins, Intravenous/therapeutic use
KW - Humans
KW - Live Birth
KW - Female
KW - Randomized Controlled Trials as Topic
UR - https://www.scopus.com/pages/publications/105005515424
U2 - 10.1016/j.jri.2025.104541
DO - 10.1016/j.jri.2025.104541
M3 - Review
C2 - 40403511
AN - SCOPUS:105005515424
SN - 0165-0378
VL - 170
JO - Journal of Reproductive Immunology
JF - Journal of Reproductive Immunology
M1 - 104541
ER -